We previously identified the mouse and human Glipr1 and GLIPR1/RTVP-1 genes, respectively, as direct p53 targets with proapoptotic activities in various cancer cell lines, including prostate cancer (PCa). Intratumoral injection of an adenoviral vector capable of efficient transduction and expression of Glipr1 (AdGlipr1) yielded promising therapeutic results in an orthotopic, metastatic mouse model of PCa. AdGlipr1-transduced macrophages (Mf/Glipr1) generated greater surface expression of CD40, CD80 and major histocompatibility complex class II molecules and greater production of interleukin 12 (IL-12) and IL-6 in vitro than control macrophages did. Mechanistic analysis indicated that increased production of IL-12 in Mf/Glipr1 depends on activation of the p38 signaling cascade. Mf/Glipr1 injected into orthotopic 178-2BMA tumors in vivo resulted in significantly suppressed prostate tumor growth and spontaneous lung metastases and longer survival relative to those observed in controltreated mice. Furthermore, these preclinical data indicate the generation of systemic natural killer cell activity and tumorspecific cytotoxic T lymphocyte responses. Trafficking studies confirmed that intratumorally injected Mf/Glipr1 could migrate to draining lymph nodes. Overall, our data suggest that this novel gene-modified cell approach is an effective treatment avenue that induces antitumor immune responses in preclinical studies.
INTRODUCTION
Estimates are that there will be 317 080 newly diagnosed cancers of the genitourinary tract in American men and 51 820 deaths caused by these cancers in 2010; prostate cancer (PCa) alone would account for 69% of those genitourinary cancers and 64% of genitourinary cancer deaths. 1 PCa is androgen sensitive, and androgen-deprivation therapy is one of the main treatment modalities in the clinical management of PCa patients with advanced, metastatic disease. Although patients with metastatic PCa can benefit from androgen-deprivation therapy at the initial stage, this approach is palliative rather than curative. Salvage cytotoxic therapy is associated with considerable morbidity with minimal survival benefit. 2 Therefore, there is a critical need to develop new and effective therapeutic approaches including gene-and cell-based therapies.
The tumor suppressor gene p53 is the most commonly mutated gene in human cancer. 3 In PCa, p53 mutations are found in relatively low frequencies in early, localized tumors, but occur in much higher frequencies in advanced, hormone-refractory metastatic tumors, and have prognostic value in locally advanced disease following androgen deprivation and radiotherapy. 4, 5 We previously identified a novel mouse gene, glioma pathogenesisrelated protein 1 (HGNC-approved gene symbol, Glipr1), as a p53 target gene and homolog to the human gene Glioma pathogenesisrelated protein 1 (HGNC-approved gene symbol, GLIPR1). 6 GLIPR1 or RTVP-1 (RTVP1 (ref. 7) ), has also been identified in human glioblastoma cells and is a marker of myelomonocytic differentiation in macrophages. 8, 9 Moreover, we have confirmed that GLIPR1 expression in human PCa, especially in metastatic tumors, is significantly lower than it is in normal prostate, owing to methylation in the regulatory region of this gene in PCa cells. 10 Functional analysis demonstrated that overexpression of both Glipr1 and GLIPR1 in vitro in various mouse and human cancer cell lines leads to apoptosis independently of p53 status. 6, 10 Adenoviral vector-mediated Glipr1 (AdGlipr1) transduction in an orthotopic metastatic murine prostate model resulted in extension of animal survival through multiple effects, such as reduced metastasis to lung, suppression of tumor-associated angiogenesis and increased infiltration of macrophages and CD8 + T cells into the tumor. 11 Glipr1-related antitumor immunostimulatory activities were confirmed and extended in subsequent studies. For example, administration of a novel Glipr1 gene-modified tumor cell vaccine to mice had substantial antitumor activity in a preclinical model of recurrent PCa. 12 This work led to the conduct of a phase I/II neoadjuvant clinical trial that involves adenoviral vector-mediated GLIPR1 therapy before radical prostatectomy in men with PCa (IND13033).
However, systemic administration of viral vectors is currently not an effective method for targeting metastatic disease, owing to low initial viral titers, immune inactivation, nonspecific adhesion and loss of particles. 13, 14 Alternative approaches have been tested, including gene-modified cell therapy approaches that focus on the delivery of therapeutic genes to the PCa, such as interleukin 12 (IL-12) genemodified macrophage therapy. 15 The results of that study demonstrated suppression of tumor growth and spontaneous lung metastasis, induction of systemic antitumor immune response and prolongation of survival in mouse orthotopic models of metastatic PCa.
We also previously showed that the number of tumor stromaassociated macrophages is inversely correlated with tumor progression in human PCa. 16 We thus speculate that gene-modified macrophages would not only provide a stable cellular vehicle but also promote intrinsic macrophage-specific tumor cytotoxicity and stimulate antitumor lymphocytes.
Thus, we undertook this study, in which we showed that AdGlipr1-transduced macrophages (Mf/Glipr1) have enhanced surface expression of CD40, CD80 and major histocompatibility complex (MHC) class II molecules and produce IL-12 via a p38-dependent mechanism. Intratumoral injection of Glipr1 gene-modified macrophages in vivo resulted in statistically significant suppression of prostate tumor growth, suppression of spontaneous lung metastases and increased overall survival rate in a preclinical mouse model of metastatic PCa. Furthermore, we demonstrated AdGlipr1-stimulated systemic natural killer (NK) cell activity and tumor-specific cytotoxic T lymphocyte (CTL) responses.
RESULTS

Transduction with AdGlipr1 induces Glipr1 expression
Peritoneal exudate macrophages were transduced with increasing multiplicities of infection (MOIs) of AdGlipr1 and incubated for 24 or 48 h, and then an MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay was performed to determine the viability of the transduced macrophages (Figure 1a ). At 24-and 48 h after infection, there was no significant reduction in cell viability with up to 200 MOI, but a significant reduction in cell viability was found at 400 MOI (24 h, P¼0.0148; 48 h, P¼0.0010) compared with the control group (MOI 0) at similar intervals. Glipr1 protein levels in macrophages were also determined and compared by western blotting 48 h after AdGlipr1 and Adbgal transduction at the indicated MOI (Figure 1b ). AdGlipr1 transduction of macrophages led to a dose-dependent increase in Glipr1 expression, whereas the expression did not change with increasing Adbgal MOI. On the basis of these results, we selected the AdGlipr1 MOI of 100 for use in the studies reported here.
In vitro characterization of AdGlipr1-transduced macrophages To investigate the characteristics of Mf/Glipr1, we analyzed the cell surface expression and production of cytokines. Cytometric analysis showed that Mf/Glipr1, compared with the control non-transduced macrophages (Mf) and those transduced with b-galactosidase (Mf/ bgal), had up to a threefold increase in cell surface expression of MHC II and CD40 molecules, a moderate increase of CD80 antigen expression and a slight change in CD86 expression (Figure 2) .
Quantitative reverse-transcription PCR (RT-PCR) analysis revealed significant changes in cytokine RNA expression levels, specifically in Mf/Glipr1, compared with Mf and Mf/bgal (Table 1) . Among these changes, the most interesting were those involving type 1 (M1) and type 2 (M2) cytokines. 17 Significantly increased expression levels of specific proinflammatory and M1 cytokines IL-1a, IL-12 p40, IL-12 p35 and IL-6 were documented. In contrast, the mRNA levels of the M2 cytokines IL-2, IL-4 and IL-10 were minimally affected by both Adbgal and AdGlipr1 transduction, and the tumor necrosis factor-a mRNA levels were moderately increased by AdGlipr1 transduction. Additionally, inducible nitric oxide synthase (NOS2) and Arg1 expression increased by 33 and 3 times, respectively, in Mf/Glipr1.
Protein levels of the cytokines in the culture medium of Mf/Glipr1, as analyzed by enzyme-linked immunosorbent assay (ELISA), were similar to those found on quantitative RT-PCR: secretion of IL-12 and IL-6 proteins increased significantly, whereas tumor necrosis factor-a and IL-10 levels did not show any statistically significant change ( Figure 3 ).
Analysis of MAPK signaling pathways in AdGlipr1-transduced macrophages
To investigate the role of mitogen-activated protein kinases (MAPKs) in the production of cytokines by the transduced macrophages, we analyzed the phosphorylated forms of c-Jun N-terminal kinase (JNK; P-JNK), p38 (P-p38) and extracellular signal-regulated kinase (ERK; P-ERK) by using western blotting with specific anti-phosphokinase antibodies (Abs). Figure 4a shows that transduction of macrophages by AdGlipr1, compared with the non-transduced and bgal-transduced controls, increased the induction of phosphorylation of JNK, p38 and ERK. The total levels of these proteins were unaffected (Figure 4a ), indicating that Glipr1 stimulated the activity of, but not the levels of, MAPKs.
To further understand the role of the individual MAPK pathways on cytokine production by Mf/Glipr1, we used SP600125, SB203580 and U0126, which are specific inhibitors of JNK, p38 and ERK MAPK activity, respectively ( Figure 4b Gene-modified macrophage prostate cancer therapy K Tabata et al and U0126 suppressed AdGlipr1-mediated phosphorylation in a dosedependent manner. We also tested the effect of these MAPK inhibitors on the secretion of IL-12 in Mf/Glipr1 by using ELISA (Figure 4c To evaluate potential antimetastatic effects of Mf/Glipr1 in this PCa model, we analyzed the extent of lung metastasis 14 days after the treatment. As indicated in Figure 5b , the Mf/Glipr1-treated group had significantly fewer macroscopic spontaneous lung metastases (mean, 2.0) than the Hanks balanced salt solution-(7.1), Mf-(5.9), Adbgal-(6.7) and Mf/bgal (5.9)-treated groups (P¼0.0036, P¼0.0204, P¼0.0071 and P¼0.0204, respectively). However, the number of lung metastases in the Mf/Glipr1-treated group was not statistically significantly different than that in the AdGlipr1-treated group (2.0 vs 2.8; P¼0.6205). Figure 5c is a cumulative Kaplan-Meier survival plot for the treated mice; the mean survival time periods for the control groups treated with Mf and Mf/bgal were 22.7 and 23.0 days, respectively, whereas For each gene, a validated primer set from the Harvard Medical School Primer Bank was used (primer ID; http://pga.mgh.harvard.edu/primerbank/index.html). Levels of expression were determined on qRT-PCR analysis by using the 2 ÀDDCt method. Each value for Mf/bgal and Mf/ Glipr1 represents the fold changes relative to the value for the non-transduced macrophages (Mf, set as 1 for each gene). The data are presented as means with standard deviation calculated based on the results of four independent measurements. Analysis of variances between Mf/bgal and Mf/Glipr1 group were performed using unpaired t-test and P-values were calculated (ANOVA). Significant differences between Mf/Glipr1 and Mf/bgal expression levels of cytokines are indicated as *Po0.01 or **Po0.001.
that for the Mf/Glipr1-treated group was 27.8 days. These differences were statistically significant according to Mantel-Cox log-rank analysis (vs Mf, Po0.0001; vs Mf/Adbgal, P¼0.0011). On necropsy, no obvious cause of death was found other than extensive tumor load, splenic trauma or abundant ascites.
Kinetics analysis of treatment activities
The kinetics of the treatment activities were analyzed in tumors from three to four mice harvested at sequential points before the end of the time course. As shown in Figure 6a , the tumors grew rapidly between 7 and 14 days after injection of the 178-2 BMA cells. However, significant suppression of tumor weight was observed on both days 7 and 14 after treatment in the Mf/Glipr1-treated group compared with the Mf-treated (day 7, 313 vs 825 mg, P¼0.0054; day 14, 1200 vs 2910 mg, Po0.0001) and Mf/bgal-treated groups (day 7, 313 vs 690 mg, P¼0.0372; day 14, 1200 vs 2400 mg, Po0.0001). The spleen of each animal was also weighed at the time of euthanasia ( Figure 6b) ; the average weight on day 0 was 62.7 mg. In the Mf/Glipr1-treated group, the spleen weight significantly increased to a maximum of 185.3 mg on day 7, compared with that in the Mf-(142.5 mg) and Mf/bgal (134.8 mg)-treated groups (P¼0.0227 and P¼0.0077, respectively), after which it decreased to 118.25 mg (similar to the control groups) on day 14.
The serum levels of IL-12 in the Mf/Glipr1-treated animals gradually increased, with a peak on day 5, and then decreased until day 14 (Figure 6c ), whereas the levels in the Mf-and Mf/bgal-treated animals did not change significantly during the time course.
AdGlipr1-transduced macrophages induce a systemic immune response
To detect whether systemic immune responses possibly resulted from the treatment of the mouse prostate tumors with Mf/Glipr1, we isolated splenocytes from mice bearing Mf-, Mf/bgal-and Mf/ Glipr1-treated tumors and analyzed the NK and CTL activities. Figure 7a shows that NK activities in splenocytes isolated from the Mf/Glipr1-treated mice were statistically significantly greater than they were in the Mf-and Mf/bgal-treated mice 2 days after treatment at effector-to-target (E/T) ratios of 100:1 (P¼0.0012 and P¼0.0067, respectively) and 50:1 (P¼0.0003 and P¼0.0027, respectively). Additionally, splenocytes isolated from mice 14 days after treatment were evaluated for their specific ability to lyse 178-2 BMA cells in vitro (Figures 7b and c) . A statistically significant increase in CTL activity in Mf/Glipr1-treated mice was observed relative to that in Mf-and Mf/bgal-treated mice 7 days after treatment at the E/T ratios of 100:1 (P¼0.0081 and P¼0.0381, respectively) and 25:1 (P¼0.0055 and P¼0.0007, respectively; Figure 7b) . The difference in CTL activity between treatment groups was less pronounced at day 14, although on average it was still greater in Mf/Glipr1-treated mice (Figure 7c ). To confirm that CD8 + T cells were responsible for this activity, we selectively depleted CD4 + and CD8 + cells from the splenocytes by Ab-mediated complement lysis before performing the CTL assay (Figure 7d) . A significant reduction of lytic activity was observed when CD8 + effector cells were depleted but not when CD4 + effector cells were depleted (P¼0.0071, Mann-Whitney test), thus confirming our hypothesis that CD8 + cells have a role in tumor cell lysis.
AdGlipr1-mediated macrophages migrate to draining lymph nodes
We prepared fluorescently labeled macrophages using the cell-linker compound PKH26-PCL, as described in Materials and methods. We then infected these fluorescent macrophages with AdGlipr1 and Adbgal and injected them directly into 178-2BMA orthotopic tumors. The prostate, draining lymph nodes, livers and lungs were harvested 
Mφ/ Glipr1
Figure 3 Production of cytokines by AdGlipr1-transduced macrophages. Isolated macrophages (Mf) were transduced with Adbgal (Mf/bgal) and AdGlipr1 (Mf/Glipr) at 100 MOI and incubated for 48 h. The growth medium was changed 48 h after transduction. After an additional 48 h, the supernatant was collected from triplicate wells and the cytokine concentration relative to that of the controls was determined using ELISA. Bars, s.e.; *Po0.05; and **Po0.01.
Gene-modified macrophage prostate cancer therapy K Tabata et al 24 and 72 h after injection and were evaluated for macrophage migration by studying tissue sections under a fluorescence microscope. At 24 h, fluorescent macrophages were restricted to the prostate (data not shown). At 72 h, the Mf/Glipr1-treated cells had migrated to the cortices of the lymph nodes, draining from the prostate with greater efficiency than had the Mf/bgal-treated cells (Figure 8 ). The migration seemed to be confined to lymph nodes at this interval, because fluorescent macrophages were not detected in the livers and lungs (data not shown).
DISCUSSION
We previously demonstrated that orthotopic delivery of adenoviral vector-mediated Glipr1/mRTVP-1, a direct p53 target gene, into mouse PCa tumors significantly suppressed their growth and metastasis to the lung. 11 In addition, we documented that intratumoral injection of AdGlipr1 generates widespread immunostimulatory activities in vivo, including the induction of macrophages within the primary tumor and the increased generation of IL-12. Additional studies showed that a Glipr1 gene-modified tumor cell vaccine had significant antitumor activity-accompanied by systemic antitumor immunity-in a preclinical model of recurrent PCa in mice. 12 We further demonstrated the successful genetic modification of murine peritoneal exudate macrophages with adenoviral vectors and presented evidence that intratumoral injection of murine IL-12 recombinant adenoviral vector (AdmIL-12)-transduced macrophages is safe and effective in a preclinical model of metastatic PCa. 15 On the basis of these results, we decided to conduct this study to evaluate the potential efficacy of Glipr1 gene-modified macrophage therapy in our established preclinical mouse models of metastatic PCa. Macrophages are prominent in the stromal compartment of virtually all types of malignancy. Tumor-associated macrophages (TAMs) arise from monocyte precursors that migrate from the bloodstream into both primary and secondary tumors at an early stage in their development. 17 Some TAMs, recognized as M1 macrophages, are activated by proinflammatory cytokines such as interferon-g and IL-1b and tumor necrosis factor-a and are capable of lysing tumor cells, presenting tumor-associated antigens to T cells and expressing immunostimulatory (type 1) cytokines such as IL-12 to stimulate the proliferation and antitumor functions of T and NK cells. [17] [18] [19] However, these activities can be suppressed by other tumor-derived cytokines (type 2), including IL-4, IL-10, transforming growth factorb1, prostaglandin E 2 and macrophage colony-stimulating factor. [20] [21] [22] [23] In contrast to M1 TAMs, M2 TAMs are activated through an 'alternative' program by IL-4 and IL-13, have poor antigen-presenting capability and produce factors that suppress T-cell proliferation and activity and promote angiogenesis. 17, 24 We previously showed that the numbers of TAMs in direct contact with PCa cells correlate positively with the Gleason score, whereas the numbers of TAMs within the cancer stroma were inversely associated with multiple clinical and pathological markers of disease progression and with its recurrence after surgery. 16 The presence of large numbers of TAMs correlate with a favorable prognosis in gastric and colorectal cancers and melanoma. [25] [26] [27] In stark contrast, increased numbers of TAMs are also associated with shorter survival in patients with breast and esophageal squamous cell carcinomas. 28, 29 Overall, it is apparent that the status of tumor progression, tumor cell compartmentalization and, more importantly, the activation status of macrophages are critical determinants of macrophage activities and their effects.
Our in vitro data demonstrated that the AdGlipr1-transduced macrophages (Mf/Glipr1) expressed significantly higher levels of type 1 cytokines (IL-1a, IL-6 and IL-12) and secreted more IL-12 and IL-6 than the Mf control and Mf/bgal cells did, although no statistically significant changes in the expression levels of type 2 cytokines (IL-2, IL-4 and IL-10) were found among the Mf/Glipr1, Figure 6 Kinetics analysis. (a) The tumor weight was lower (that is, growth suppression) in the Mf/Glipr1-treated group than that in the control groups by day 7 and continued through day 14 after the treatments. (b) The spleen weight was significantly higher in the Mf/Glipr1-treated group than that in the control groups at day 7 after the treatments. (c) Serum IL-12 levels gradually increased in Mf/Glipr1-treated group, with a peak on day 5, but the level returned to that of the control groups at day 14. Bars, s.e.; *Po0.05; and **Po0.001.
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Mf/bgal and Mf control groups. It was notable that Glipr1 transduction also increased expression of cell surface MHC II molecules, which may indicate polarization toward the M1 phenotype. 30 The Mf/ Glipr1 cells also demonstrated a remarkably strong increase in inducible nitric oxide synthase (NOS2 expression, an M1 marker) and a moderate increase in Arg1 expression (an M2 marker) relative to the expression levels in Mf and Mf/bgal cells. In accordance with in vitro results, the serum levels of IL-12 gradually increased in the Mf/ Glipr1-treated group, with a peak on day 5, but did not increase in the control groups. Overall, these results indicate that AdGlipr1 might stimulate peritoneal exudate macrophages to develop into polarized M1 macrophages. In this study, we found increased NK activity on day 2 and CTL activity on day 7 after treatment with Mf/AdGlipr1. These increases in activity may have resulted from the generation of a Th1 response and the increased surface expression of MHC class II, CD80 and CD40 that was induced by AdGlipr1 in peritoneal exudate macrophages.
However, this CTL activity in the Mf/AdGlipr1-treated group decreased by day 14, perhaps because of the decreased serum levels of IL-12. The increase in CTL activity observed in Mf/AdGlipr1-treated mice was clearly CD8 dependent, because it was almost completely ablated by depletion of CD8 + cells but not by depletion of CD4 + cells. These immunostimulatory activities are very similar to those demonstrated previously after AdGlipr1 injection into orthotopic tumors using a similar model system. 11 AdGlipr1 also induced phosphorylation of JNK, p38 and ERK in murine peritoneal exudate macrophages; inhibition of P-JNK and P-ERK had no effect on IL-12 production, whereas inhibition of P-p38 by SB203580 suppressed IL-12 production. These results indicate that the p38 pathway mediates Glipr1-induced IL-12 production in peritoneal exudate macrophages. The expression of p38 family members is regulated differently in various tissues and cell lineages. The p38 MAPK pathway has been proposed to function in the regulation of cytokine production, B-and T-cell proliferation and differentiation, the innate immune response, cell cycle control and apoptosis. 31 The results of several studies have demonstrated that activation of the p38 MAPK pathway is involved in IL-12 regulation. 32, 33 Mice deficient in MKK3, an upstream kinase of p38, were defective in the production of IL-12 by antigen-presenting cells. 34 Lipopolysaccharide-stimulated macrophages isolated from MKK3-deficient mice produced normal levels of IL-6, IL-1b, tumor necrosis factor-a and IL-1b but, in contrast, IL-12 production was significantly reduced in MKK3-deficient macrophages. 34 We previously showed that GLIPR1 upregulation activates the JNK signaling cascade and is required for GLIPR1-mediated apoptosis in cancer cells. 35 Consistent with those previously reported findings, overexpression of GLIPR-1 increased the phosphorylation of JNK in macrophages in this study. However, activated JNK signaling does not lead to apoptosis in peritoneal exudate macrophages. This, together with our previous results, suggests that the apoptotic responses to JNK inhibition are cell line dependent and that the involvement of JNK in apoptosis is complex and still not well understood. 36 
M/ gal M/Glipr1
72 h Figure 8 In vivo macrophage trafficking. On day 7 after injection of 178-2BMA metastatic prostate cancer cells, the resulting orthotopic tumors were injected with PKH-26CL-fluorescently labeled macrophages that had been transduced with Adbgal (Mf/bgal) or AdGlipr1 (Mf/Glipr1). The draining lymph nodes were harvested 72 h after macrophage treatment and tissue sections were examined with fluorescence microscopy. These data imply that the Mf/Glipr1 migrated into the cortex area of draining lymph nodes with higher efficiency than that observed with Mf/bgal cells.
Another interesting finding in this study was the increased degree of migration of macrophages to the draining lymph node in mice injected with Glipr1 gene-modified macrophages. In addition to their role in innate immunity, M1 macrophages have been shown to phagocytose apoptotic tumor cells. This function, together with the production of higher levels of IL-12 and increased surface expression of CD40 and MHC class II molecules, suggests that some Mf/Glipr1 cells could function as tumor antigen-presenting cells. Their increased migration to the lymph nodes may be anatomic evidence of this possibility. In the cortex of a lymph node, the Mf/Glipr1 subgroup could come into contact with naive lymphocytes, thereby initiating the process of antigen presentation. This process could be a bridge between the phagocytotic function of M1 macrophages and the induction of systemic immunity, such as the increased CTL activity seen in the Mf/Glipr1-treated mice. Further studies are warranted to determine the mechanisms underlying the effect of Glipr1 in promoting the migration of macrophages to the lymph nodes.
Overall, the results of this study demonstrate that Glipr1 genemodified macrophages generated antitumor effects in a preclinical mouse model of metastatic PCa. Intratumoral injection of AdGlipr1 and Mf/Glipr1 produced similar antitumor effects, such as reduced tumor weights and fewer lung metastases. However, treatment with a viral vector alone has limitations owing to systemic vector toxicity and production of antivirus Ab that preclude repeated injections. Genemodified cell therapy, such as we investigated, overcomes both of these limitations and could be considered for further studies, including clinical trials.
MATERIALS AND METHODS
M/ collection and cultivation
Peritoneal exudate macrophages were collected by lavage, 5 days after intraperitoneal injection of 2 ml of thioglycollate medium (Becton, Dickinson and Company Diagnostic Systems, Sparks, MD, USA) into 129/Sv mice. The collected cells were seeded in Petri dishes with Dulbecco's modified Eagle's medium (Invitrogen Corporation, Carlsbad, CA, USA) enriched with 10% heat-inactivated fetal bovine serum. The cells were allowed to attach for 2 h before being washed with phosphate-buffered saline to eliminate non-adherent cells. Macrophage purity was assessed by flow cytometry, and the cells were replated before being infected with the adenoviral vector.
Glipr1/mRTVP-1 cDNA was cloned and sequenced as previously described and inserted into pCA3. 6 Replication-defective adenoviral vector was generated by cotransfection with pJM17 into the 293 human embryonic kidney cell line. 37 As a control adenoviral vector, Adbgal was prepared as described previously. 38 Each adenoviral vector was isolated from a single plaque, expanded in 293 cells and purified by double cesium-gradient ultracentrifugation; the titer was assessed by performing a plaque assay on the infected 293 cells and expressed as plaque-forming units. The adenoviral vectors were added to the prepared macrophages at the indicated MOI in serum-free medium for 2 h and then fresh complete medium was added for overnight incubation. Cells were collected and analyzed at indicated time points as described below.
Cell viability assay
Isolated Mf were infected with increasing MOI of AdGlipr1, as described above, and incubated in 96-well dishes at 2.0Â10 4 cells per well for 48 h. The viability of Mf was evaluated using an MTS Cell Titer 96 Aqueous One Solution cell proliferation assay (Promega, Madison, WI, USA), according to the manufacturer's instructions. Briefly, Mf were cultured for 48 h in conditions as described above. MTS substrate was added to the medium at a ratio of 20 ml of MTS for every 100 ml of culture medium. Then, Mf were incubated for 1 h at 37 1C. After incubation, 100 ml from each well was analyzed in triplicate on a colorimetric plate reader at an absorbance of 490 nm.
In vitro characterization of transduced macrophages
Peritoneal exudate macrophages were seeded in 24-well plates in triplicate. The next day, the medium was aspirated, the adherent cells were washed gently with phosphate-buffered saline and the macrophages were infected with 100 MOI of AdGlipr1 or Adbgal. Fresh medium was added after 2 h. Cells (0.5-1.0Â10 6 ) from each group of Mf, Mf/bgal and Mf/Glipr1 were then harvested and stained with fluorescein isothiocyanate-conjugated monoclonal Abs against murine cell surface molecules (F4/80 (AbD Serotec, MorphoSys UK Ltd., Oxford, UK), I-A b , CD80, CD86, CD40 and appropriate isotype controls (Pharmingen, San Diego, CA, USA)). Cytometric analysis was performed by using an EPICS XL-MCL (Coulter Electronics, Westbrook, ME, USA) flow cytometer. The mean fluorescence intensity and percentage of positive cells were used to make the between-group comparisons.
Analysis of cytokine expression in transduced macrophages
For RT-PCR analysis of cytokine expression, total RNA was isolated from cultured macrophages 48 h after transduction using a RiboPure RNA isolation kit (Applied Biosystems/Ambion, Austin, TX, USA). Total RNA (2 mg) was reverse transcribed using a high-capacity cDNA reverse-transcription kit (Applied Biosystems, Foster City, CA, USA). The generated cDNA (1 ml per reaction) was analyzed by performing quantitative RT-PCR with validated primer sets from the Harvard Medical School Primer Bank 39 (http://pga.mgh. harvard.edu/primerbank/index.html and Table 1 ) and using a Platinum SYBR Green qPCR SuperMix-UDG kit (Invitrogen) according to the manufacturer's protocol. Reactions were monitored by using Invitrogen's One-Step real-time PCR system with the SYBR Green protocol settings. The relative changes in gene expression were calculated using the DDC t method (gene expression level¼2
ÀDDCt ) according to the following formula: DC t ¼C t (treated)ÀC t (control), in which C t represents the cycle threshold value normalized to the expression levels of GAPDH (glyceraldehyde 3-phosphate dehydrogenase), a house keeping gene. Melting curve analysis was carried out for each pair of primers to confirm the specificity of the RT-PCR reaction.
We also used the Taqman qRT-PCR assay (Applied Biosystems) to assess the levels of mouse IL-12 p35 and IL-12 p40.
Quantitation of cytokines by ELISA
Blood was drawn from the inferior vena cava of the mice at the time of euthanasia and allowed to clot, and the serum was collected after centrifugation. The serum and tissue culture supernatants were stored at À80 1C. The levels of IL-12 and IL-6 were quantitatively determined by commercially available ELISA kits, per the manufacturer's protocol (Invitrogen/BioSource).
Western blotting
Peritoneal exudate macrophages transduced with Adbgal or AdGlipr1 at 100 MOI were incubated for 48 h as described before. The cell lysates were then electrotransferred and immunoblotted against primary Abs. Next, the primary Abs were detected using horseradish peroxidase-conjugated anti-rabbit or antimouse IgG and visualized by using enhanced chemiluminescence. The primary Abs that selectively recognize the phosphorylated forms of JNK, p38 MAPK and ERK were all purchased from Cell Signaling Technology (Beverly, MA, USA). Generation of Glipr-1(mRTVP-1) was previously described. 6 To determine the amounts of precipitated JNK, p38 MAPK and ERK, blots were stripped and reprobed using phosphorylation state-independent anti-JNK, anti-p38 MAPK and anti-ERK Abs.
Orthotopic mouse PCa model
The mouse PCa cell line 178-2 BMA was originally derived from a bone metastasis obtained from Zipras/myc9-infected urogenital sinus tissue from p53-heterozygous 129/Sv mice in the metastatic mouse prostate reconstitution model system, as previously described. 40, 41 Cell preparation and the orthotopic injections were carried out as described previously. 15 Uninfected macrophages (Mf), Adbgal-transduced macrophages (Mf/bgal) and AdGlipr1-transduced macrophages (Mf/Glipr1) were each resuspended in Hanks balanced salt solution at a concentration of 4Â10 7 cells per ml, and 25 ml of the resulting suspension was injected into established prostate tumors 7 days after the tumor cell injection. For the selected groups, in situ delivery of Adbgal or AdGlipr1 at Gene-modified macrophage prostate cancer therapy K Tabata et al an optimal dose of 5Â10 8 plaque-forming units was made by injection into established tumors. A 30-gauge needle was placed through an intracapsular, transprostatic tract before tumor penetration to minimize leakage at the time of needle withdrawal. Animals were euthanized on the fourteenth day after the treatment or at selected time periods for kinetic analyses. However, for the survival analysis, animals were monitored daily and euthanized when they became moribund. The sample size was 10 mice per treatment group, except for the kinetics analyses, in which 3 or 4 mice per treatment group were euthanized on each specified day. At necropsy, all animals were carefully evaluated for gross metastases. The primary tumors and spleens were removed and weighed. The spleens were placed in sterile medium and splenocytes were purified and used for NK and CTL assays, as described below. Tumor tissues were fixed in formalin, embedded in paraffin cut into 5-mm sections and stained with hematoxylin and eosin for histological examination. The lungs were removed and placed in Bouin's solution for fixation. The next day, two independent observers counted the total number of spontaneous lung metastases with the aid of a dissecting microscope, and the average of their two counts was reported. 38 All mice were maintained in facilities accredited by the American Association for Accreditation of Laboratory Animal Care, and all experiments were conducted in accordance with the principles and procedures outlined in the NIH's Guide for the Care and Use of Laboratory Animals.
In vitro cytolytic assays
Splenocytes were collected at selected time periods and used for NK and CTL assays. NK activity was determined by lysis of 51 Cr-labeled YAC-1 tumor cells (the prototypic NK-cell target cells) with splenocytes derived from tumorbearing animals, essentially as described previously. 38 The YAC-1 cell line was obtained from the American Type Culture Collection (Manassas, VA, USA). CTL activity was determined by lysing target 51 Cr-labeled, interferon-gstimulated 178-2 BMA cells with splenocyte-derived T lymphocytes.
Effector cells were generated in vitro by incubating spleen cells from tumorbearing mice (1.8Â10 7 cells per well) with mitomycin C-treated 178-2 BMA cells (1.2Â10 7 cells per well) in 12-well plates for 5 days in the presence of antitransforming growth factor-b 1 Ab (30 mg ml À1 ) and IL-2 (20 U ml À1 ). Target 178-2 BMA cells were incubated with interferon-g (100 U ml À1 ) for 2 days and then radiolabeled with 100 mCi of 51 Cr for 45 min at 37 1C. Cells with different effector-to-target (E/T) ratios were incubated for 4 h at 37 1C. Supernatants were collected and counted in a gamma counter, and the percentage of specific lysis was calculated as described previously. 42 In vitro depletion of CD8 + and CD4 + T cells was accomplished by treating splenocytes immediately after their isolation with supernatants from the hybridoma HO-2.2 (anti-Lyt 2.2) or GK1.5 (anti-L3T4; American Type Culture Collection) in a cytotoxicity medium (RPMI-1640 with 25 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) and 0.3% bovine serum albumin) purchased from Cedarlane Laboratories (Burlington, ON, Canada). Ab was allowed to bind at 4 1C for 1 h and then rabbit complement (Accurate Chemical & Scientific Corporation, Westbury, NY, USA) was added; the cells were incubated at 37 1C for 1 h. The cells were then incubated, as described above, for preparing effector cells. The specificity and effectiveness of the procedure were confirmed by flow cytometric analysis of splenocytes 24 h after complement-mediated lysis.
Trafficking study of transduced macrophages in vivo
The fluorescent cell-linker compound PKH26-PCL (Sigma-Aldrich Corporation, St Louis, MO, USA) for phagocytic cell labeling was injected intraperitoneally into 129/Sv donor mice. Labeled macrophages were collected from the donor mice 2 days later by peritoneal lavage with culture medium and plated as described above. Macrophages were infected with AdGlipr1 or Adbgal at an MOI of 100. Then, 1Â10 6 infected macrophages were injected into orthotopic 178-2 BMA tumors. The mice were euthanized 24 and 72 h after treatment with macrophages, and the prostates, draining lymph nodes, lungs and livers were collected and fixed in Zamboni's fixative (2% paraformaldehyde, 10% picric acid and 0.1 M phosphate buffer (pH 7.2)) for 12 h at 4 1C, embedded in O.C.T. compound and frozen. Serial 6-mm sections were prepared from these samples using a cryostat mounted in antifading medium and examined with the use of a fluorescence microscope.
Statistical analysis
ANOVA (analysis of variance) software (unpaired t-test) was used to compare the tumor weights, number of spontaneous metastases, the results of ELISA and cytolytic assay. Kaplan-Meier survival analysis results were evaluated by using the Mantel-Cox log-rank test. All analyses were performed by using Statview 5.0 software (SAS Institute, Cary, NC, USA).
